Key Takeaways
- “The trial has ended” may mean the participant stopped treatment, finished follow-up, the local site closed, the primary endpoint was reached or the global study ended. Ask which date is meant.
- Continued access to an investigational intervention is not automatic approval, an indefinite free supply or a clinical recommendation for every participant.
- Post-trial access should be planned before enrolment. The 2024 Declaration of Helsinki says arrangements must be made for participants who still need an intervention identified as beneficial and reasonably safe, unless an ethics committee approves an exception [1].
- A good exit packet includes treatment exposure, final safety plan, unresolved events, next clinical decision, record contacts and the route for learning study results.
- International participants need a named clinician at home and a written division of responsibility; the research database is not a substitute for continuing medical care.
Content
A trial can be “over” for one patient while study visits continue for everyone else. The last dose may arrive months before the final safety call. A Chinese site may close while other countries keep recruiting. The primary analysis may be complete while survival follow-up continues for years. These distinctions decide who can prescribe treatment, who watches late effects, which records still need updating and when results may become available.
The useful question is not simply “When does the trial end?” It is: Which research activity is ending for me, what care replaces it, and who is responsible on the next day?
Put the five clocks on one page
Ask the site to date each of these separately:
Milestone · What it usually means · What it does not necessarily mean
Last investigational dose/procedure · protocol treatment stops for this participant · safety follow-up and data collection are finished
End-of-treatment visit · response, toxicity, medicines and transition are reviewed · the participant is discharged from all study contact
End of participant follow-up · no further protocol visits are planned, subject to later safety requests allowed by consent/rules · the site or global trial has closed
Primary completion · last participant completes collection for the primary outcome · all secondary, survival or long-term safety analyses are complete
Study completion/early termination · protocol-defined global work ends or is stopped · product approval, publication or post-trial supply occurs immediately
Also record the database lock and planned unblinding/result dates if available. A registry status such as “completed” describes the study record; it does not tell an individual patient whether treatment or follow-up is complete.
“End of treatment” and “withdrawal” are not interchangeable
Treatment may stop because the planned course finished, the disease progressed, toxicity emerged, the participant chose to stop, the investigator judged continuation unsafe, supply ended or the study closed. The participant may still agree to clinic, phone or record-based follow-up.
Conversely, a participant can withdraw from some or all research activity. ICH E6(R3) expects the consent process to explain follow-up for people who stop the investigational product, withdraw or are discontinued, and how their data will be handled [2]. Ask the team to document separate choices about:
- future intervention;
- in-person study visits;
- remote safety or survival contact;
- access to routine medical records;
- use of already collected data;
- storage and future use of samples.
Do not sign an ambiguous “withdrawal” form while acutely ill. Ask which activities stop and which legally or ethically remain. Already recorded safety information generally cannot simply be erased if doing so would make the research record misleading.
Build the exit packet before leaving the site
The final handover should be usable by a clinician who has never seen the protocol. Request:
- study title, registry and sponsor protocol numbers, site and principal investigator;
- participant code and emergency/safety contact that remains active;
- actual intervention or blinded assignment status, dose, route, lot where clinically relevant, and first/last exposure dates;
- operations, radiation, cell collection/infusion, implants or conditioning treatment performed;
- best response and the criteria/date used, without presenting a research endpoint as guaranteed personal benefit;
- current symptoms, clinically important abnormalities, unresolved adverse events and their follow-up owner;
- complete medication list, dose changes, prophylaxis and stop dates;
- pending pathology, imaging, laboratory, genetic or immune-monitoring results;
- late-effect risks and exact surveillance schedule;
- reproductive precautions, donation restrictions and infection/device alerts where relevant;
- the next standard-care appointment and clinician;
- post-trial access decision, status and fallback plan;
- how and when individual assignment and overall study results may be communicated.
Keep original Chinese records and a checked translation. For imaging, request DICOM files rather than screenshots. For cell, gene and implant trials, preserve product/device identifiers and emergency management instructions for the long term.
Post-trial access is a plan, not a slogan
The 2024 Declaration of Helsinki strengthened the ethical expectation: before the trial starts, arrangements must exist for participants who still need an intervention found beneficial and reasonably safe in the trial; any exception requires ethics approval, and the consent discussion must disclose the arrangement [1]. CIOMS similarly recommends deciding the level, duration, financing, delivery and monitoring of continued care before the study and explaining the transition to participants [3].
That principle still requires an individual and regulatory pathway. “I improved” may be important but does not alone establish a favourable long-term risk–benefit balance. An observed response can coincide with delayed toxicity, natural fluctuation, other treatment or a biased early impression. The investigator should consider current disease status, objective response, adverse effects, alternatives and the evidence available across the study.
Ask for a written answer to six questions:
- Is continued access planned in the protocol or a separate document?
- Who qualifies, and who makes the clinical decision?
- Through which legal route will the product/device be supplied?
- How long can access continue, and what stops it?
- Who pays for product, visits, tests, travel and complication care?
- What happens if supply, approval, site capacity or patient eligibility changes?
The main routes after trial treatment
Route · What changes · Questions to settle
Approved routine care · product has the necessary market authorisation and is prescribed clinically · approved indication, availability in China/home country, price, insurance, prescriber
Open-label extension/rollover study · a new or amended research protocol continues access and data collection · new eligibility, consent, visits, randomisation/blinding transition, end date
Protocol continuation · original protocol includes treatment beyond the primary analysis · maximum duration, progression/toxicity rules, site funding and supply
Expanded/compassionate route · unapproved intervention is provided under a specific legal/ethical mechanism · eligibility, regulator/ethics review, institution, monitoring, costs, supply
Standard or alternative treatment · research product stops and an available clinical option begins · washout, interactions, timing, reimbursement, records and response baseline
Observation/supportive care · no active anticancer/disease-modifying intervention is chosen · symptom care, surveillance, escalation triggers and goals
An extension study is still research, not a private refill. New consent, eligibility and data collection can apply. Commercial launch is also not the same as immediate access: approval may cover a different indication, dose or country; procurement and insurance can take longer.
China-specific access claims need careful verification
China’s Drug Administration Law allows a defined expanded-use pathway at the institution conducting the trial for drugs being studied for serious life-threatening diseases without effective treatment, when there is possible benefit, ethics review and informed consent [4]. China also has provisions for expanded clinical trials of certain unapproved medical devices for life-threatening disease without effective treatment [5].
These mechanisms do not create an automatic personal right to indefinite post-trial supply. They have conditions, institutional limits and oversight. A coordinator saying “compassionate use” is not enough. Ask the hospital GCP/research office to identify the governing route, ethics approval, responsible investigator, product accountability, monitoring and written cost policy. Never accept unlabelled stock sent outside the authorised hospital channel.
What if the study stops early?
Early termination can follow safety findings, clear benefit or futility, poor recruitment, product quality, funding/business decisions or regulator/ethics action. The reason matters.
The site should tell participants promptly what stopped, whether treatment or only recruitment ended, immediate medical actions, whether blinding changes, which safety visits remain and how routine care will resume. China’s drug-registration rules allow regulators to require protocol adjustment, suspension or termination when participant safety cannot be ensured or serious safety information is mishandled [6].
Do not rely on a press release. Ask for a participant-specific letter and verify the public registry status. If the reason is proprietary and details are limited, the team should still provide enough information for a safe treatment decision.
Long-term follow-up can outlive the treatment center visit
Cell and gene therapies, implants, radiation, immune therapies and some reproductive interventions may require long follow-up for delayed effects. Long-term follow-up is not proof that harm is expected; it is a defined way to detect low-frequency or late risks.
Clarify the schedule, tests, acceptable local laboratories, remote options, travel requirements, compensation and what happens if the Chinese site or sponsor closes. A protocol that requires years of contact should have a successor contact and data-transfer plan. The 2020 China GCP requires protocols to define adverse-event follow-up methods and duration and sites/sponsors to retain essential records under applicable requirements [7].
When a local doctor performs surveillance, agree on units, imaging technique, sample timing and what triggers an urgent report. A translated lab result without reference ranges or assay method may not be comparable.
Who pays after the final study visit?
During a trial, the sponsor may pay for protocol-required product and tests while routine care remains the patient’s or insurer’s responsibility. After treatment ends, that split may change immediately.
Request a dated cost matrix for:
- investigational product/device and dispensing;
- extension-study visits and research tests;
- routine disease monitoring;
- treatment of ongoing or late adverse events;
- travel, lodging, interpreter and sample shipping;
- approved commercial treatment after launch;
- emergency care at home;
- record translation and transfer.
“Free drug” does not mean free care. Conversely, an invoice does not prove the product is legally marketed. Confirm payer, billing entity, claim documents, end date and currency. Do not make a large personal payment to a recruiter for purported post-trial access.
Results, assignment and individual findings arrive on different schedules
Participants may want three different things:
- treatment assignment: whether they received the investigational or comparator arm;
- individual results: laboratory, imaging, genetic or incidental findings relevant to them;
- overall results: what happened across all study groups.
Unblinding one participant too early can affect follow-up or analysis, so the protocol may delay assignment disclosure. Individual results require a plan for analytical validity, clinical significance and counselling. Overall results should include harms and uncertainty, not only a headline response rate.
The Declaration of Helsinki requires positive, negative and inconclusive results to be made publicly available [1]. WHO calls for key results in a public registry within 12 months of study completion as a global disclosure norm, while recognising that publication timing can differ [8]. This does not guarantee that every participant receives a personalised plain-language summary on the same date. Before exit, ask where the registry record is, who will notify participants and how contact details can be updated without keeping an unnecessary full medical file open.
Data and samples do not automatically disappear at trial end
The database may be cleaned, queried, locked, analysed, inspected and archived after visits finish. Samples may be destroyed, retained for protocol tests or stored for future research depending on consent and applicable approvals.
Ask for the consent clauses covering retention period, coded identifiers, overseas transfer, genetic analysis, future use, commercial collaboration, re-contact and withdrawal options. China’s 2023 ethics measures cover research using people, human biological samples and health information and require participant rights and continuing oversight to remain central [9]. Ending clinical contact does not cancel privacy duties.
If a participant withdraws permission for future optional sample research, request written confirmation of what can be destroyed, what has already been used or irreversibly de-identified, and what must be retained for trial integrity or law. Avoid promises that all copies can be retrieved from completed analyses.
A cross-border exit plan
Four weeks before the planned last on-site visit, send the receiving clinician a draft handover and ask what is missing. Before departure:
- schedule the next appointment at home;
- confirm enough standard medicines and legal transport documentation;
- decide who acts on pending results;
- test the study contact and secure file-transfer route;
- record the safety reporting end date and late-risk alerts;
- clarify whether future Chinese visits are research-required or optional clinical care;
- keep a fallback plan if continued access is denied or delayed;
- save the registry link and sponsor/site closure contact.
The transition is complete only when the receiving clinician accepts responsibility and has the information needed to act—not when the patient boards the flight.
Medical disclaimer: Post-trial access and follow-up depend on the protocol, individual clinical circumstances, ethics review, product status and applicable law. This guide does not promise continued supply or replace advice from the investigator and the clinician responsible for ongoing care.
FAQ
If the study treatment helped me, must the sponsor keep providing it?
There is a strong ethical expectation that post-trial arrangements be planned for participants who still need an intervention found beneficial and reasonably safe, but the actual route, eligibility, duration, supply and exceptions must be defined and reviewed. Ask for the written plan; do not rely on a verbal promise.
Does “study completed” on a registry mean my follow-up is over?
No. It is a study-level status. Your safety, survival or long-term follow-up schedule may continue, or your own participation may have ended earlier.
When will I learn whether I received placebo or active treatment?
The protocol determines unblinding. Ask for the expected trigger and communication route; urgent clinical unblinding may occur earlier when it would change care.
Can I receive the investigational drug in my home country after leaving China?
Only if a lawful supply and monitoring route exists there. Shipping from a Chinese site or recruiter is not automatically permitted. The sponsor, both treating teams and relevant regulatory/ethics pathways must be checked.
What records matter most at the last visit?
Obtain actual exposure and procedure details, current medicines, unresolved events, pending tests, surveillance schedule, post-trial access decision, responsible clinicians, emergency contact and the route for results and long-term follow-up.
Sources
- World Medical Association — Declaration of Helsinki (2024), Post-Trial Provisions and Results
- ICH — E6(R3) Good Clinical Practice, Final Guideline
- CIOMS — International Ethical Guidelines for Health-related Research Involving Humans
- Drug Administration Law of the People’s Republic of China — Articles 21–24
- NMPA/NHC — Interpretation of Expanded Clinical Trials for Medical Devices
- State Administration for Market Regulation — Provisions for Drug Registration
- China Drug Good Clinical Practice (2020, effective at review date)
- World Health Organization — Public Disclosure of Clinical Trial Results
- National Health Commission of China — Ethical Review Measures for Life-Science and Medical Research Involving Humans
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The existing nurse–patient conversation is pleasant but indistinguishable from a routine appointment. A replacement should show a clear transition: a final study timeline ending, a handover packet moving to a home-country clinician, and separate branches for follow-up, routine care and authorised continued access, without readable medical data or promises of ongoing treatment.